FLIP: Molecular switch between apoptosis and necroptosis

Molecular Carcinogenesis

Volumn 53, Issue 9, 2014, Pages 675-685

  Gong, Jingjing ^a   Kumar, Saikartik A ^a,c   Graham, Gilian ^a,b   Kumar, Addanki P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Apoptosis; Autophagy; FLIP; Necroptosis; Programmed cell death

Indexed keywords

FLICE INHIBITORY PROTEIN; ISOPROTEIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; HUMAN; MOLECULAR INTERACTION; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NECROSIS; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; HUMANS; NECROSIS; NEOPLASMS;

EID: 84906086148     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22027     Document Type: Article

References (87)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
3. Sun Y, Peng ZL. Programmed cell death cancer. Postgrad Med J 2009; 85:134-140.
4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-1462.
5. Yang J, Epling-Burnette PK, Painter JS, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 2008; 111:1610-1616.
6. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol 2004; 24:2627-2636.
7. Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med 2006; 203:1295-1305.
8. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997; 16:2794-2804.
9. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403:98-103.
10. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
11. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 2004; 23:2934-2949.
12. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2010; doi: 10.1016/J.canlet.2010.10.009 Available online 10 November 2010.
13. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320-22329.
14. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137:1112-1123.
15. Vandenabeele P, Galluzzi L, Berghe TV, Kroemer G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11:700-714.
16. Feoktistova M, Geserick P, Kellert B, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43:449-463.
17. Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43:432-448.
18. Long JS, Ryan KM. New frontiers in promoting tumor cell death: Targeting apotposis, necroptosis and autophagy. Oncogene 2012; 31:5045-5060.
19. Sridhar S, Botbol Y, Macian F, Cuervo AM. Autophagy and disease: Always two sides to a problem. J Pathology 2012; 226:255-273.
20. Lee JS, Li Q, Lee JY, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 2009; 11:1355-1362.
21. Iyer AK, Azad N, Talbot S, et al. Antioxidant c-FLIP Inhibits Fas Ligand-Induced NF-kappaB Activation in a Phosphatidylinositol 3-Kinase/Akt-Dependent Manner. J Immunol 2011; 187:3256-3266.
22. Haldar SM, Stamler JS. S-Nitrosylation at the interface of autophagy and disease. Mol Cell 2011; 43:1-3.
23. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1:112-119.
24. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009; 14:674-686.
25. Thapa RJ, Basagoudanavar SH, Nogusa S, et al. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 2011; 31:2934-2946.
26. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr Cancer Drug Targets 2008; 8:37-46.
27. Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers 2011; 3:1639-1671.
28. L. J Cell Biol 2010; 190:377-389.
29. Gao S, Wang H, Lee P, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 2006; 36:463-483.
30. Ganapathy M, Ghosh R, Jianping X, et al. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 2009; 15:1601-1611.
31. Bedolla RG, Gong J, Prihoda TJ, et al. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS ONE 2012; 7:e44917.
32. Kump E, Ji J, Wernli M, Häusermann P, Erb P. Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene 2008; 27:3856-3864.
33. Chanvorachote P, Nimmannit U, Wang L, et al. Nitric oxide negatively regulates Fas CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE inhibitory protein. J Biol Chem 2005; 280:42044-42050.
34. S. J Virol 2003; 77:2651-2662.
35. Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 2005; 304:244-255.
36. Higuchi H, Yoon JH, Grambihler A, Werneburg N, Bronk SF, Gores GJ. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 2003; 278:454-461.
37. L turnover. Cell 2006; 124:601-613.
38. Haimerl F, Erhardt A, Sass G, Tiegs G. Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 2009; 284:495-504.
39. Stagni V, Mingardi M, Santini S, Giaccari D, Barila D. ATM kinase activity modulates cFLIP protein levels: Potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 2010; 31:1956-1963.
40. Llobet D, Eritja N, Domingo M, et al. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 2011; 178:1529-1543.
41. Zhang L, Gallagher PJ. Mind bomb 1 regulation of cFLIP interactions. Am J Physiol Cell Physiol 2009; 297:C1275-C1283.
42. Fang Y, Sharp GC, Braley-Mullen H. Effect of transgenic overexpression of FLIP on lymphocytes on development and resolution of experimental autoimmune thyroiditis. Am J Pathol 2011; 179:1211-1220.
43. Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H. Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukocyte Biol 2010; 87:1019-1028.
44. L. Fertil Steril 2010; 93:1407-1414.
45. Huang QQ, Perlman H, Huang Z, et al. FLIP: A novel regulator of macrophage differentiation and granulocyte homeostasis. Blood 2010; 116:4968-4977.
46. Giampietri C, Petrungaro S, Coluccia P, et al. C-Flip overexpression affects satellite cell proliferation and promotes skeletal muscle aging. Cell Death Dis 2010; 1:e38.
47. Coffey F, Manser T. Expression of cellular FLIP by B cells is required for their participation in an immune response. J Immunol 2010; 184:4871-4879.
48. Qiao G. Li Z, Minto AW, et al. Altered thymic selection by overexpressing cellular FLICE inhibitory protein in T cells causes lupus-like syndrome in a BALB/c but not C57BL/6 strain. Cell Death Differ 2009; 17:522-533.
49. Schattenberg JM, Nagel M, Kim YO, et al. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012; 303:G498-G506.
50. Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie 2012; 94:287-299.
51. Yu W, Tiwary R, Li J, et al. Alpha TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinogen 2010; 49:964-973.
52. Lee J, Hwangbo C, Lee JJ, Seo J, Lee JH. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol Rep 2010; 23:229.
53. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2009; 17:883-894.
54. Wang W, Fang Y, Sima N, et al. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP. Apoptosis 2011; 16:55-66.
55. Wang W, Zhao J, Wang H, et al. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression. Exp Cell Res 2010; 316:2456-2464.
56. Zhao L, Yue P, Lonial S, Khuri FR, Sun SY. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol Cancer Ther 2011; 10:2415-2425.
57. Rushworth SA, Zaitseva L, Langa S, et al. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359.
58. Su L, Liu G, Hao X, et al. Death Receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer 2011; 47:2471-2478.
59. Hurwitz JL, Stasik I, Kerr EM, et al. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer 2011; 48:1096-1107.
60. L from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17:1354-1367.
61. Yoshiba S, Iwase M, Kurihara S, et al. Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis. Oncol Rep 2011; 25:645.
62. Abedini M, Muller E, Bergeron R, Gray D, Tsang B. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2009; 29:11-125.
63. Kauh J, Fan S, Xia M, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 2010; 5:e10376.
64. Jung SN, Park IJ, Kim MJ, et al. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 2009; 315:2433-2441.
65. Um HJ, Oh JH, Kim YN, et al. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chem Biol Interact 2010; 186:36-42.
66. Bleumink M, Köhler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2010; 18:362-370.
67. Bijangi-Vishehsaraei K, Saadatzadeh MR, Huang S, Murphy MP, Safa AR. 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem 2010; 342:133-142.
68. Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol 2011; 132:429-439.
69. Chen F, Zhu HH, Zhou LF, Wu SS, Wang J, Chen Z. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2010; 23:1457-1462.
70. Ho TC. Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone-induced apoptosis in hepatocellular carcinoma. Anticancer Res 2011; 31:1173-1180.
71. Chen F, Guo J, Zhang Y, et al. Knockdown of c FLIPL enhanced AD510 anti death receptor 5 monoclonal antibody induced apoptosis in human lung cancer cells. Cancer Sci 2009; 100:940-947.
72. Siegelin M, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int 2009; 55:423.
73. Siegelin M, Gaiser T, Habel A, Siegelin Y. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett 2009; 283:230-238.
74. Siegelin MD, Siegelin Y, Habel A, Gaiser T. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett 2009; 453:92-97.
75. Chen L, Chung I, Hsueh C, et al. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ 2010; 17:1463-1473.
76. Haag C, Stadel D, Zhou S, et al. Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011; 60:225-237.
77. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ. Interleukin-8 signaling attenuates TRAIL-and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7:2649-2661.
78. Van Geelen CMM, Pennarun B, EK WBV, et al. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 2010; 37:1031-1041.
79. Mitchell C, Park MA, Zhang G, et al. Extrinsic pathway-and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther 2007; 6:3101-3112.
80. Palacios C, Yerbes R, López-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006; 66:8858-8869.
81. Son Y, Kim EH, Kim JY, et al. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 2007; 67:8274-8284.
82. Day TW, Safa AR. RNA interference in cancer: Targeting the anti-apoptotic protein c-FLIP for drug discovery. Mini Rev Med Chem 2009; 9:741-748.
83. Geserick P, Drewniok C, Hupe M, et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008; 27:3211-3220.
84. Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359-366.
85. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32:1450-1458.
86. L via inhibition of EGFR pathway. Biochem Pharmacol 2009; 77:1328-1336.
87. Ye H, Li Y, Melamed J, et al. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer. J Urol 2009; 181:872-877.